Volume 3.11 | Mar 22

Mesenchymal Cell News 3.11, March 22, 2011.
     In this issue: Science News | Current Publications | Industry News | Policy News | Events

CD146 Expression on Primary Non-Hematopoietic Bone Marrow Stem Cells Correlates to In Situ Localization
Researchers have characterized the phenotype of primary human non-hematopoietic bone marrow mesenchymal stem cells and found that all
assayable CFU-F were highly and exclusively enriched not only in the lin-/CD271+/CD45-/CD146+ stem cell fraction, but also in lin-/CD271+/CD45-/CD146-/low cells. [Blood]



social_default_facebook_icon.jpg “Like” Cell Therapy News on Facebook for a chance to win an Amazon gift card!

Webinar: ALDHbr Cells and Regenerative Medicine
Aldehyde Dehydrogenase bright (ALDHbr) cells have been used in preclinical models and human clinical trials in applications such as critical limb ischemia, ischemic stroke, acute liver failure and ischemic heart failure.1 Learn more about how ALDHbr cells could be used in regenerative medicine by registering today for an exclusive webinar presented by Dr. Andrew E. Balber of Cicada Biopharmaceutical Consulting.

Join us on April 7 at:
10AM EST (ideal for Europe) | 2PM EST (ideal for Americas) | 8PM EST (ideal for Asia-Pacific)

Reviewed in Balber AE. Stem Cells (in press). DOI: 10.1002/stem.613.
Dr. Balber holds equity in and is a consultant to Aldagen, Inc., a company that is developing research, diagnostic, and therapeutic products based on detecting and isolating ALDHbr cells.


Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Stem Cell Society Singapore (SCSS) 2012 Symposium: Stem Cell Based Therapy

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy
Researchers used cardiac MRI (CMR) in patients with left ventricular dysfunction related to remote myocardial infarction to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling. [Circ Res]

Cardiac Mesenchymal Stem Cells Contribute to Scar Formation After Myocardial Infarction
Since the rapid accumulation and activity of cardiac fibroblasts is critical for proper scar formation, researchers hypothesized that infarct fibroblasts are generated by a cardiac-resident progenitor cell population. [Cardiovasc Res]

NOS Inhibition Synchronizes Calcium Oscillations in Human Adipose Tissue-Derived Mesenchymal Stem Cells by Increasing Gap-Junctional Coupling
Researchers demonstrate that undifferentiated adipose tissue-derived mesenchymal stem cells display robust oscillations of intracellular calcium which may be associated with stem cell maintenance since oscillations were absent in endothelial cell differentiation medium supplemented with FGF-2. [J Cell Physiol]

Fibrin Microbeads (FMB) Loaded with Mesenchymal Cells Support their Long Term Survival While Sealed at Room Temperature
Fibrin microbeads (FMB) were developed as hard biodegradable cell carriers. The FMB could efficiently isolate mesenchymal stem cells from different sources and support the expansion of matrix-dependent cell types in a 3D culture in slow rotation. [Tissue Eng Part C Methods]

BMP-12 Treatment of Adult Mesenchymal Stem Cells In Vitro Augments Tendon-Like Tissue Formation and Defect Repair In Vivo
Researchers characterized the differentiation of rat bone marrow-derived mesenchymal stem cells (BM-MSCs) into tenocyte-like cells in response to bone morphogenetic protein-12 (BMP-12). [PLoS ONE]

Purified Mesenchymal Stem Cells Are an Efficient Source for iPS Cell Induction
Here, researchers generated induced pluripotent stem (iPS) cells from PDGFRα+ Sca-1+ (PαS) adult mouse mesenchymal stem cells and PDGFRα− Sca-1− osteo-progenitors, and compared the induction efficiency and quality of individual iPS clones. [PLoS ONE]

Evaluation of Senescence in Mesenchymal Stem Cells Isolated from Equine Bone Marrow, Adipose Tissue and Umbilical Cord Tissue
The purpose of this study was to compare the onset of replicative senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue and umbilical cord tissue. [Stem Cells Dev]

Electroporation-mediated Transfer of SOX Trio Genes (SOX-5, SOX-6, SOX-9) to Enhance the Chondrogenesis of Mesenchymal Stem Cells
The purpose of this study was to test the hypothesis that the SOX trio genes (SOX-5, SOX-6, and SOX-9) have a lower level of expression during the chondrogenic differentiation of mesenchymal stem cells (MSCs) compared to chondrocytes, and that the electroporation-mediated gene transfer of SOX trio promotes chondrogenesis from human MSCs. [Stem Cells Dev]

MicroRNA Expression during Osteogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells from Bone Marrow
Researchers isolated and cultured human mesenchymal stromal cells (MSCs) and osteo-differentiated MSCs from four individual donors. miRNA expression in MSCs and osteo-differentiated MSCs was investigated using miRNA microarrays. [J Cell Biochem]


Beike Biotechnology Upgrades Its Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies
Beike Biotechnology Co. Ltd., China’s leading stem cell research and regenerative medicine company, announced an agreement with USA-based
ThermoGenesis Corp. to employ new, cutting edge stem cell processing and storage technology across its adult stem cell collection, processing, and archive platform. [Beike Biotechnology Co. Ltd. Press Release]

Mesoblast CEO Named Biospectrum Asia Person of the Year 2011
Regenerative medicine company Mesoblast Limited announced that Chief Executive Officer Professor Silviu Itescu has been named BioSpectrum
Asia Pacific Person of the Year 2011. [Mesoblast Limited Press Release]

Terrapinn Stem Cells 645x110


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW The 5th UK Mesenchymal Stem Cell (MSC) Meeting
July 1, 2011
Birmingham, United Kingdom

Visit our events page to see a complete list of events in the mesenchymal cell community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Field Applications Specialist – Cell Therapy (Pall Corporation) 

Implementation Coordinator – Maternity Leave Contract (STEMSOFT Software Inc.)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mesenchymal Cell News: Archives | Events | Contact Us